HCM
HUTCHMED (China) Limited NASDAQ Listed Mar 16, 2016$13.67
-1.09%
vs $13.82
Mkt Cap $2.4B
52w Low $9.77
51.9% of range
52w High $17.29
50d MA $12.15
200d MA $13.20
P/E (TTM)
133.4x
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.1x
ROE
36.9%
P/FCF
-30.2x
RSI (14)
61.20
ATR (14)
$0.32
Beta
0.45
50d MA
$12.15
200d MA
$13.20
Avg Volume
86.1K
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Cheung Kong Center · Hong Kong · HK
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | BMO | 0.14 | 0.10 | -31.0% | 11.39 | -2.5% | -5.4% | +3.3% | +3.8% | +0.2% | -0.2% | — |
| Mar 5, 2026 | BMO | 2.50 | 0.01 | -99.8% | 13.65 | +0.4% | +1.5% | +0.0% | -0.6% | +0.9% | +4.9% | — |
| Aug 7, 2025 | BMO | 1.46 | 2.60 | +78.1% | 16.31 | -7.6% | -8.0% | +3.2% | -0.9% | +4.3% | -0.8% | — |
| Jul 2, 2025 | BMO | -0.32 | 1.35 | +526.0% | 15.69 | -0.8% | +0.8% | -2.5% | +3.3% | +2.3% | -2.0% | — |
| Mar 19, 2025 | BMO | 0.04 | 0.07 | +75.0% | 16.18 | +1.6% | -0.3% | -7.1% | +0.7% | -3.1% | -2.7% | — |
| Sep 30, 2024 | AMC | — | 0.03 | — | 19.53 | +0.8% | +2.4% | +4.1% | -4.2% | +5.3% | -0.2% | — |
| Jul 31, 2024 | BMO | -0.39 | 0.01 | +103.8% | 19.44 | -2.8% | -4.9% | -1.9% | +0.6% | +10.9% | -2.9% | — |
| Jun 10, 2024 | BMO | -0.13 | 0.07 | +157.7% | 18.08 | -0.9% | -0.9% | +0.1% | +4.0% | -2.8% | -1.3% | — |
| Mar 12, 2024 | BMO | -0.13 | -0.20 | -53.1% | 14.96 | +7.2% | +9.2% | +13.7% | -9.6% | +4.9% | -2.7% | — |
| Feb 28, 2024 | BMO | -1.08 | -0.04 | +96.3% | 15.21 | +1.1% | -0.7% | +0.3% | -0.2% | -8.5% | +7.7% | — |
| Jul 31, 2023 | BMO | -0.52 | 0.10 | +118.7% | 14.07 | +5.2% | +7.9% | -6.6% | +11.6% | +4.2% | -15.8% | — |
| Jun 27, 2023 | BMO | — | 0.47 | — | 11.15 | +1.3% | +3.9% | -3.5% | +0.5% | +6.8% | -1.2% | — |
| Jun 20, 2023 | AMC | — | 0.49 | — | 11.95 | -0.6% | -9.5% | +4.6% | -4.8% | +3.4% | +3.9% | — |
| May 23, 2023 | BMO | — | -0.60 | — | 13.09 | +0.2% | +0.5% | -2.5% | -4.8% | +9.7% | -7.4% | — |
| Feb 28, 2023 | AMC | -1.02 | -0.12 | +88.5% | 16.55 | +4.8% | +3.6% | +1.2% | +0.4% | -2.5% | -2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 8 | HSBC Securities | Upgrade | Hold → Buy | — | $14.09 | $14.00 | -0.6% | -1.5% | -2.2% | -3.3% | -2.3% | +6.6% |
| Sep 3 | Daiwa Securities | Upgrade | Hold → Buy | — | $12.04 | $13.60 | +13.0% | +17.2% | -0.1% | -1.5% | -2.2% | -3.3% |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | $13.77 | $13.78 | +0.1% | +0.9% | +4.9% | -2.6% | -1.5% | +2.1% |
| Sep 22 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $17.04 | $16.69 | -2.1% | -2.2% | -4.0% | -0.7% | -0.6% | -0.9% |
| Jul 22 | BofA Securities | Maintains | Buy → Buy | — | $17.74 | $17.82 | +0.5% | -0.3% | -0.6% | +1.2% | -1.0% | +2.1% |
| Aug 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.44 | $18.90 | -2.8% | -4.9% | -1.9% | +0.6% | +10.9% | -2.9% |
| Nov 24 | Deutsche Bank | Upgrade | Hold → Buy | — | $18.24 | $19.21 | +5.3% | +5.5% | -0.8% | +1.4% | -3.0% | +2.7% |
| Nov 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $18.09 | $18.65 | +3.1% | +5.1% | -2.6% | +2.8% | -1.7% | -6.1% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.38 | $15.15 | -1.5% | -3.4% | -3.7% | -2.9% | +1.0% | +6.6% |
| Jul 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.75 | $13.20 | +3.5% | +6.0% | +2.7% | +6.1% | -3.9% | +4.0% |
| Aug 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $13.93 | $13.90 | -0.2% | -1.9% | +3.5% | -2.0% | +0.0% | +0.2% |
| Aug 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.07 | $11.85 | -1.8% | -1.5% | +3.8% | +7.6% | +4.5% | +0.4% |
| Sep 22 | Goldman Sachs | Downgrade | Buy → Neutral | — | $38.18 | $37.21 | -2.5% | -5.3% | +3.7% | -2.5% | +2.0% | -2.5% |
| Aug 3 | Jefferies | Maintains | Buy → Buy | — | $42.79 | $42.80 | +0.0% | +0.0% | -2.3% | +2.0% | -1.6% | +2.4% |
| Mar 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.20 | $19.97 | +9.7% | +10.3% | -15.3% | +8.2% | -17.4% | +5.5% |
| Feb 20 | Goldman Sachs | Maintains | Buy → Buy | — | $27.44 | $28.31 | +3.2% | +0.0% | -4.6% | -4.5% | -3.3% | -1.0% |
| Nov 19 | CLSA | Maintains | Buy → Buy | — | $23.60 | $23.60 | +0.0% | +1.1% | -1.1% | -0.2% | +1.6% | +0.0% |
| Mar 4 | Deutsche Bank | Maintains | Buy → Buy | — | $26.82 | $27.26 | +1.6% | -0.7% | +1.9% | +0.9% | -3.5% | +1.9% |
| Oct 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.39 | $30.77 | +1.3% | -1.7% | -3.5% | -4.9% | +1.3% | -1.0% |
| Apr 11 | BofA Securities | Maintains | Buy → Buy | — | $13.30 | $13.36 | +0.5% | +0.1% | +0.5% | +0.3% | +0.4% | +0.1% |
| Apr 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.30 | $13.36 | +0.5% | +0.1% | +0.5% | +0.3% | +0.4% | +0.1% |
| Apr 11 | Stifel | Maintains | Buy → Buy | — | $13.30 | $13.36 | +0.5% | +0.1% | +0.5% | +0.3% | +0.4% | +0.1% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Schroder Investment Management Group | 1,477,494 | $22M | Reduced | Mar 2026 |
| 2 | M&g Plc | 255,468 | $4M | Reduced | Mar 2026 |
| 3 | Aia Group Ltd | 291,229 | $3M | — | Jun 2026 |
| 4 | Bnp Paribas Financial Markets | 106,504 | $2M | Added | Mar 2026 |
| 5 | Jane Street Group, Llc | 107,995 | $1M | Reduced | Dec 2025 |
| 6 | Renaissance Technologies Llc | 130,200 | $1M | Reduced | Jun 2026 |
| 7 | Xy Capital Ltd | 104,130 | $1M | Added | Jun 2026 |
| 8 | Citadel Advisors Llc | 76,122 | $819K | Added | Jun 2026 |
| 9 | Two Sigma Investments, Lp | 63,248 | $681K | New | Jun 2026 |
| 10 | Ubs Group Ag | 44,758 | $670K | Reduced | Mar 2026 |
| 11 | Morgan Stanley | 24,294 | $324K | Reduced | Dec 2025 |
| 12 | Vanguard Personalized Indexing Management, Llc | 20,425 | $306K | Added | Mar 2026 |
| 13 | Millennium Management Llc | 26,420 | $284K | Reduced | Jun 2026 |
| 14 | Bank Of America Corp /de/ | 12,489 | $187K | Reduced | Mar 2026 |
| 15 | Janney Montgomery Scott Llc | 17,310 | $186K | Reduced | Jun 2026 |
| 16 | Summit Trail Advisors, Llc | 13,090 | $141K | — | Jun 2026 |
| 17 | Blue Trust, Inc. | 7,708 | $83K | — | Jun 2026 |
| 18 | Fmr Llc | 3,531 | $53K | — | Mar 2026 |
| 19 | Rhumbline Advisers | 3,881 | $42K | New | Jun 2026 |
| 20 | Royal Bank Of Canada | 2,660 | $40K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 11
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Tema Oncology ETF | 62,129 | $890K | Feb 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 21,833 | $313K | Feb 2026 |
| 3 | Dimensional Emerging Markets Core Equity 2 ETF | 7,822 | $117K | Jan 2026 |
| 4 | National Security Emerging Markets Index ETF | 7,022 | $101K | Feb 2026 |
| 5 | Emerging Markets Sustainability Core 1 Portfolio | 6,469 | $97K | Jan 2026 |
| 6 | EMERGING MARKETS CORE EQUITY 2 PORTFOLIO | 6,229 | $93K | Jan 2026 |
| 7 | Emerging Economies Fund | 5,709 | $82K | Feb 2026 |
| 8 | THE EMERGING MARKETS SMALL CAP SERIES | 3,324 | $50K | Jan 2026 |
| 9 | World ex U.S. Core Equity Portfolio | 2,921 | $44K | Jan 2026 |
| 10 | Dimensional World ex. U.S. Core Equity 2 ETF | 2,110 | $32K | Jan 2026 |
| 11 | Dimensional Emerging Markets Sustainability Core 1 ETF | 1,312 | $20K | Jan 2026 |
Valuation
Market Cap
$2.38B
Enterprise Value
$1.09B
P/E (TTM)
133.36x
Forward P/E
42.79x
PEG Ratio
0.00x
P/B
1.88x
P/S
4.34x
P/FCF
-30.20x
EV/EBITDA
—
Shares Out
174.6M
Financials (TTM)
Revenue
$549.1M
Net Income
$17.9M
EBITDA
-$20.5M
Free Cash Flow
-$79.0M
Op Cash Flow
-$64.8M
EPS Basic
$2.65
EPS Diluted
$0.10
EPS Forward
$0.32
Gross Margin
0.2%
Op Margin
-6.3%
Net Margin
3.3%
Balance Sheet
Total Assets
$1.75B
Total Liab.
$501.8M
Total Equity
$1.25B
Cash
$1.37B
LT Debt
$68.2M
Book Value/Sh
$7.29
Debt/Equity
0.08x
Current Ratio
4.96
Quick Ratio
4.83
Returns & Growth
ROE
36.9%
ROA
26.1%
ROIC
-3.3%
Rev Growth YoY
-12.7%
EPS Growth YoY
+1101.8%
Price Returns
2W
-3.1%
1M
+8.6%
3M
+36.8%
6M
-1.1%
12M
-19.8%
Technicals
52W High
$17.29
52W Low
$9.77
50d MA
$12.15
200d MA
$13.20
RSI (14)
61.20
ATR (14)
$0.32
Beta
0.45
Avg Volume
86K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.50
High
$17.50
Low
$17.50
Median
$17.50
Data updated apr 26, 2026 10:47am
· Source: financialmodelingprep.com